Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sema4 Holdings Corp. - Warrant (NQ:SMFRW)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 9, 2023 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	0.0181 (200)
Ask (Size)	0.0260 (40)
Prev. Close	0.0240
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	105,429
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

January 09, 2023

From GeneDx Holdings Corp.

Via GlobeNewswire

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 30, 2022

Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation

From Sema4

Via GlobeNewswire

Performance

More News

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

December 05, 2022

From Sema4

Via GlobeNewswire

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

November 14, 2022

From Sema4

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm

November 06, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

November 04, 2022

From Sema4

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm

October 31, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

October 31, 2022

From Sema4

Via GlobeNewswire

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

October 27, 2022

From Sema4

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm

October 26, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels

October 26, 2022

From Sema4

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TuSimple, Kohl’s, Bed Bath & Beyond, and Sema4 and Encourages Investors to Contact the Firm

October 21, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm

October 16, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders

October 13, 2022

From Sema4

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm

October 11, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm

October 06, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study

October 05, 2022

From Sema4

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm

October 02, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR NOTICE: Sema4 Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SMFR; SMFRW

September 20, 2022

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Investor Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders to Actively Participate

September 16, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

EQUITY ALERT: Rosen Law Firm Encourages Sema4 Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SMFR, SMFRW

September 13, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sema4 Holdings Corp. (SMFR, SMFRW) Investors

September 12, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

September 09, 2022

Via ACCESSWIRE

SEMA4 ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sema4 Holdings Corp. and Encourages Investors to Contact the Firm

September 08, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

SEMA4 ALERT: Bragar Eagel & Squire, P.C. is Investigating Sema4 Holdings Corp. on Behalf of Sema4 Stockholders and Encourages Investors to Contact the Firm

August 18, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

Frequently Asked Questions

Is Sema4 Holdings Corp. - Warrant publicly traded?

Yes, Sema4 Holdings Corp. - Warrant is publicly traded.

What exchange does Sema4 Holdings Corp. - Warrant trade on?

Sema4 Holdings Corp. - Warrant trades on the Nasdaq Stock Market

What is the ticker symbol for Sema4 Holdings Corp. - Warrant?

The ticker symbol for Sema4 Holdings Corp. - Warrant is SMFRW on the Nasdaq Stock Market

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.